Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. - Wikidata - awgldk - TriplyDB

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

http://www.wikidata.org/entity/Q42771088

about

Novel targeted therapies for eosinophil-associated diseases and allergy IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.Local immunoglobulin e in the nasal mucosa: clinical implications.Current challenges and controversies in the management of chronic spontaneous urticaria.Targeted therapeutics for severe refractory asthma: monoclonal antibodies.Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells.High affinity targeting of CD23 inhibits IgE synthesis in human B cells.Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in four dogs.Biologic agents for severe asthma patients: clinical perspectives and implications.Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study.Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history.Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

P2860

Q34444620-FAA2552F-ABD8-403E-A89F-077722E5DC58 Q37554168-C05900E6-ABBD-4F80-9928-071006136CA0 Q38370137-8AF1FF98-647F-4B60-8CC4-06E069046545 Q38547047-559FC2D2-2670-4BEF-A020-0331EDE8AD91 Q38790815-955FC9CF-9DCC-4921-855B-54A696507A38 Q38982481-66E32749-47DD-4109-B52A-2F7CD9382E00 Q41482365-2D8DBB20-5F82-40EE-8B4C-3862CA025C61 Q42043725-D637EFF9-5B09-4753-9ADE-EDD9E27F0776 Q44865598-F2054AD5-32C8-40A0-ABDC-BE56D3DF4702 Q47576873-BA7E7D5C-52B8-4503-99B6-44115C5B63B2 Q48104072-75F7DB18-77DA-4BA8-86F8-ED15BD7F19C5 Q52584472-72D4ADCE-506F-423E-AA5D-A0E806BBF586 Q55370774-F8B70C45-6EC6-4BC1-847F-1522C84574E0

P2860

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

http://www.wikidata.org/entity/Q42771088

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

@en

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

@nl

type

label

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

@en

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

@nl

prefLabel

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

@en

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

@nl

P1433

Q42771088-32012591-CC17-4251-9EAA-AAB70055C681

P1476

Q42771088-9F18B951-1F93-4294-A874-B815D28432F7

P2093

Q42771088-07ED6EF7-4883-4482-96F9-02D26026ED98

Q42771088-6451F941-72F6-4E22-9A91-63A0AC7196CF

Q42771088-AFC37096-1078-4B3C-9846-4BF40C6FAF27

Q42771088-F1E72A35-30BC-4104-B221-DE2DE479DD1D

P2860

Q42771088-0CAD5063-14CA-4BB8-8C27-FF1228BCAEC0

Q42771088-10DD3D40-6057-4E7D-9454-ACDEC600B419

Q42771088-1665A5F5-B43C-4035-B483-03D9B0C8BD13

Q42771088-1B23EC4A-FAAB-49A8-B7B0-FC2EB81F38BA

Q42771088-239BFEE8-4B90-4E31-813A-F15E397A8CF8

Q42771088-3CAF2249-083D-428F-9241-0D33566F7245

Q42771088-5589EF38-97A9-4497-8F97-F62749F97F6E

Q42771088-62551433-B768-4254-A917-D12630041EAA

Q42771088-69CEA903-0434-4EDE-90C8-E4E7DD75F079

Q42771088-6DDFF2A3-B7ED-46D3-978B-22F7EEEE48A9

P2888

Q42771088-D849D9E6-1E37-4964-8ABF-E17604E93372

P304

Q42771088-029C855A-B20B-4642-9CBB-0770D7C4FE1C

P31

Q42771088-BD1C1196-F7B1-4895-B24B-D18C918C119E

P356

Q42771088-04B61534-504D-4FB2-8AFE-C8E9CDAAD3DD

P433

Q42771088-4300C3AB-1ACA-4ADD-9868-65144D228F8A

P478

Q42771088-1C7336F6-F020-4E4C-9924-8C054235F92E

P577

Q42771088-A53A09C2-0E06-4E86-B4E6-CF1002EFDB1C

P5875

Q42771088-18F71911-73CF-40DA-A98C-CC0CD4FAF61B

P6179

Q42771088-79C72E17-7590-462C-9D94-FCE167557E06

P698

Q42771088-5CC6614E-E701-47D9-B0B2-B8BB9FCB91C9

P932

Q42771088-0F971C66-5F6B-4657-B74E-2AAC9CC22E16

P356

P1433

Clinical and translational allergy

P1476

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

@en

P2093

Abby L Dotson

http://www.w3.org/2001/XMLSchema#string

Lanny J Rosenwasser

http://www.w3.org/2001/XMLSchema#string

Marcia A Chan

http://www.w3.org/2001/XMLSchema#string

Nicole M Gigliotti

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacological basis of anti-IgE therapy

The IL-4 receptor: signaling mechanisms and biologic functions

Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression

The role of immunoglobulin E in allergy and asthma.

CD23: an overlooked regulator of allergic disease.

The regulation of immunoglobulin E class-switch recombination.

Soluble CD23 controls IgE synthesis and homeostasis in human B cells.

Molecular and cellular targets of anti-IgE antibodies.

Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells.

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.

P2888

P304

29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2045-7022-3-29

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256448162

http://www.w3.org/2001/XMLSchema#string

P6179

1039147598

http://www.w3.org/2001/XMLSchema#string

P698

24004581

http://www.w3.org/2001/XMLSchema#string

P932

3875359

http://www.w3.org/2001/XMLSchema#string